Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $63.67 Consensus PT from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received an average rating of “Buy” from the seven analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $63.67.

TARS has been the topic of several recent analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group boosted their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Barclays decreased their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Finally, Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $47.02 on Thursday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.80 billion, a P/E ratio of -12.34 and a beta of 0.94. The company has a 50-day moving average price of $49.18 and a 200 day moving average price of $46.72. Tarsus Pharmaceuticals has a 12-month low of $20.08 and a 12-month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.08. The firm had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Sell-side analysts anticipate that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 7,131 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the transaction, the chief executive officer now owns 70,720 shares in the company, valued at $3,273,628.80. The trade was a 9.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now directly owns 58,057 shares in the company, valued at $2,687,458.53. This represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,542 shares of company stock worth $1,581,173. Corporate insiders own 8.25% of the company’s stock.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in TARS. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth $44,000. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth $53,000. Quarry LP purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at $166,000. Finally, HighTower Advisors LLC acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at $207,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.